Interview Olivier Soula – Le Journal des Biotechs – March 2024 (FR)
BIO-Europe Spring 2024: Interview with Jérémy Benattar
Web-conference – 4th Quarter 2023 Financial Results (FR)
02/29/2024 Web-conference – Financial Results – 2023 Fourth Quarter (French) Icon check
01/10/2024 ADOCIA – Investor Presentation – Biotech Showcase/JPM24 – January 2024 Icon check
Olivier Soula – Le Revenu TV – Dec. 2023 (FR)
Web conférence – Diabète : un laboratoire pour le futur de la santé – déc. 2023 (FR)
11/28/2023 ADOCIA – Investir Day – Nov 2023 (FR) Icon check
Olivier Soula – Investival Showcase
11/13/2023 ADOCIA – LSX Investival Presentation – Nov 2023 Icon check
Olivier Soula – Le Journal des Biotechs (FR)
Jérémy Benattar – Investisseur.TV (FR)
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse (FR)
07/11/2023 EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772 Icon check
Webconference of July 6th, 2023
07/05/2023 ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing Icon check
06/23/2023 AdoShell® Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023
2022 Annual Results
01/30/2023 ADOCIA – Letter to shareholders – January 2023 Icon check
01/12/2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248. Icon check
12/29/2022 ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao Icon check
10/06/2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Icon check
Investors Webinar of Sept 20th, 2022
09/07/2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Icon check
2022 AdoShell Islets Presentation
06/23/2022 ADOCIA – Letter to Shareholders – June 2022 Icon check
06/21/2022 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Icon check
05/18/2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
05/09/2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Icon check
04/11/2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Icon check
10/14/2021 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Icon check
06/27/2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
06/02/2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
04/23/2021 ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970. Icon check
03/10/2021 Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes Icon check
09/10/2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
09/05/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/16/2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/03/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
02/21/2020 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
06/10/2019 “BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA) Icon check
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
04/15/2019 Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD.
“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”
Diabetes Obes Metab., 2019;21(7):15701575.
Icon check
04/08/2019 Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575. Icon check
04/03/2019 Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.
“BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.”
Diabetes Obes Metab., 2019;21(4):1066-1070.
Icon check
03/27/2019 Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/27/2019 Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/26/2019 “BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France) Icon check
03/26/2019 “BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France) Icon check
02/23/2019 The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)
02/23/2019 The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)
02/22/2019 “BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany) Icon check
02/21/2019 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
01/17/2019 BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab., 2019;21(4):1066-1070. Icon check
11/25/2018 Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T.
“Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.”
Diabetes Obes Metab., 2018;20(11):2627-2632.
Icon check
10/05/2018 The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps, Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
10/05/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in Subjects with T1DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
Join our mailing list. Subscribe